

بسم الله الرحمن الرحيم



HOSSAM MAGHRABY



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



HOSSAM MAGHRABY

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
على هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن


تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HOSSAM MAGHRABY



بعض الوثائق الأصلية تالفة



HOSSAM MAGHRABY



بالرسالة صفحات

لم ترد بالأصل



HOSSAM MAGHRABY

ROLE OF HELICOBACTER PYLORI IN DYSPEPSIA WITH AND WITHOUT NSAIDs INTAKE AND THE EFFECT OF THERAPY

THESIS

*Submitted in Partial Fulfillment for the M.D.
Degree in Tropical Medicine*

B14100

PRESENTED BY

MAGDY ABD EL- MAWGOOD GAD
(M.B.; B. Ch., M. Sc. Tropical Medicine)

SUPERVISED BY

PROF. SAMIR MOHAMED KABIL

Prof. and Head of the Department of Hepatology,
Gastroenterology and Infectious Diseases
Benha Faculty of Medicine
University of Zagazig

PROF.

JEAN FRANCOIS ROSSIGNOL

Clinical Professor at The University of
South Florida USA. Visiting Professor
at the Department of Hepatology,
Gastroenterology and Infectious
Diseases, Benha Faculty of
Medicine, University of
Zagazig

PROF.

MOHAMED MAGDY ATTA

Prof. of Hepatology, Gastroenterology and
Infectious Diseases
Benha Faculty of Medicine
University of Zagazig


PROF. ASHRAF KHAMIS NASSAR

Ass. Prof. of Hepatology, Gastroenterology and Infectious Diseases
Benha Faculty of Medicine
University of Zagazig.


**BENHA FACULTY OF MEDICINE
UNIVERSITY OF ZAGAZIG**

1999





وقل رب زدني علماً



ACKNOWLEDGEMENT

I wish heartily to express my deep appreciation and profound gratitude to my **PROF. SAMIR M. KABIL**, Prof. and Head of the Department of Hepatology, Gastroenterology and Infectious Disease, Benha Faculty of Medicine, University of Zagazig, for his kind close supervision and encouragement. He has his finger prints in every single piece in this thesis, his brotherly attitude touched me deeply extending his scientific contribution even more.

My sincere thanks are also to **PROF. JEAN FRANCOIS ROSSIGNOL**, Prof. of Infectious Diseases, University of South Florida, USA, for his sincere and continuous support and under his generous contribution I had the honour to complete this work.

I would like to express my deepest gratitude to **PROF. MOHAMED MAGDY ATTA**, Prof. of Hepatology, Gastroenterology and Infectious Diseases, Benha Faculty of Medicine, University of Zagazig, for continuous encouragement and guidance.

I wish to express my profound gratitude to **PROF. ASHRAF KHAMIS NASSAR**, Assistant Prof. of Hepatology, Gastroenterology and Infectious Diseases, Benha Faculty of Medicine, University of Zagazig, for his meticulous supervision, great support, kind patience and helpful suggestions throughout this work.

I am also greatly overwhelmed by the constant help and assistance overed by **DR. BAHA IHAB MONIR**, Lecturer of Pathology, University of Cairo, for performing the histological examination of this thesis.

I am greatly indebted to **PROF. FRANCIS MEGRAUD**, Laboratoire de Bacteriologie - Enfants, Centre Hospitalier Universitaire Pellegrin, Bordeaux, France, for performing the culture method of this thesis.

Heart felt thanks are also offered to all members of medical and nursing staff of the Department of Hepatology, Gastroenterology and Infectious Diseases, Benha University Hospital for their help and Friendly attitude.



ABSTRACT

In 600 patients with dyspepsia with and without NSAIDs intake and/or CLD, the overall incidence of *H. pylori* was 92%. Diagnosis of *H. pylori* was made by ELISA finger prick test, rapid urease test, histopathology and culture methods. The highest incidence of *H. pylori* (97.6%) was found in peptic ulcer and the lowest incidence (85%) in NUD. CLD and NSAIDs does not constitute an independent risk factor for contracting *H. pylori*. Duodenal ulcer was diagnosed in 104 patients (17.3%) of which 101 (97.1%) were found to be colonized with *H. pylori*. High colonization density of *H. pylori* was found in patients with DU as well as in patients with dysplasia and intestinal metaplasia with high significant correlation between the degree of colonization and activity of gastritis. This finding enforces the role played by this organism in the aetiopathogenesis of DU and adds a further confirmatory evidence that patients with high grade of colonization are more liable for changes in the surface mucosa with its possible consequences. *H. pylori* positive patients were randomly allocated to one of two treatment strategies. Either dual therapy with omeprazole (or lansoprazole) and nitazoxanide (or roxithromycin) or triple therapy with lansoprazole, roxithromycin and metronidazole (or nitazoxanide). Patients treated with triple therapy of lanzop., roxithro. and nitazoxanide showed almost 92% cure rate judged by breath test (in a subset of patients) 4 to 6 weeks after therapy. The relapse rate of *H. Pylori* was found to be 2.7% (2/73). It is concluded, therefore, that *H. pylori* is widely prevalent in patients with dyspepsia in Egypt and *H. pylori* eradication is a stable phenomenon over time.

LIST OF ABBREVIATIONS

AIDS	: Acquired immune deficiency syndrome.
CBS	: Colloidal bismuth subcitrate.
CHD	: Coronary heart disease.
CLD	: Chronic liver disease.
COX	: Cyclo-oxygenase enzyme.
DU	: Duodenal ulcer.
G17	: Gastrin 17.
GERD	: Gastroesophageal reflux disease.
GU	: Gastric ulcer.
HBsAg	: Hepatitis B surface antigen.
HBcAb	: Hepatitis B core antibody.
HCV	: Hepatitis C virus.
H.P	: Helicobacter pylori.
H.pylori	: Helicobacter pylori.
IBS	: Irritable bowel syndrome.
IgA	: Immunoglobulin A.
IgG	: Immunoglobulin G.
IgM	: Immunoglobulin M.
IL	: Interleukin.
LPS	: Lipopolysaccharide.
MAO	: Maximal acid output.
MALT	: Mucosa associated lymphoid tissue.
MHC	: Major histocompatibility complex.
MIC	: Minimum inhibitory concentration.
NSAIDs	: Non steroidal anti-inflammatory drugs.
NUD	: Non ulcer dyspepsia.
PGs	: Prostaglandins
PHG	: Portal hypertensive gastropathy.
PMN	: Polymorph nuclear leucocytes.
PCR	: Polymerase chain reaction.
PKa	Partition co-efficient
PPIs	: Proton pump inhibitors
RBS	: Ranitidine Bismuth citrate.
UBT	: Urea breath test.
TNF	: Tumour necrosis factor.

CONTENTS

	Page
* INTRODUCTION	1
* AIM OF THE WORK	3
* REVIEW OF LITERATURE :	
- Chapter I : Helicobacter pylori.....	4
- Chapter II : Dyspepsia	91
- Chapter III : NSAID – gastropathy.....	112
* PATIENTS AND METHODS	123
* RESULTS	133
* DISCUSSION	160
* SUMMARY	179
* CONCLUSIONS	182
* RECOMMENDATIONS	183
* REFERENCES.....	184
* ARABIC SUMMARY.....	

INTRODUCTION

INTRODUCTION

Since the first report of unidentified curved bacilli in the gastric mucosa by *Warren and Marshall (1983)*, there has been much interest in possible link between this organism and gastroduodenal lesions. *H. pylori*, which colonizes the antrum of the stomach has received much scientific attention and its discovery has changed the aetiological concept of peptic ulcer disease.

H. pylori is considered to be the major aetiological factor in peptic ulcer disease (*Marshall, 1994*) and a probable initiating factor in gastric carcinoma (*Blaser and Parsonet, 1994*) and gastric lymphoma (*Wother Spoon et al., 1991*).

Patients with dyspepsia are shown to have *H. pylori* present if biopsy specimens are taken at endoscopy and eradication of *H. pylori* improves patient symptoms (*O'Marain and Gilvarry, 1993*). Moreover, patients infected with *H. pylori* are more likely to have a peptic ulcer rather than a non-ulcer dyspepsia if an underlying chronic liver disease is existing (*Kabil et al., 1995 b*).

Among the pathogenic mechanisms involved in gastroduodenal mucosal injury, *H. pylori* and NSAIDs show both similar effects, such as the stimulation of gastric acid secretion and impairment of gastric mucus properties, as well as opposing effects, such as prostaglandin production, which is increased by *H. pylori* infection and decreased by NSAIDs (*Malfertheiner and Labenz, 1998*). *H. pylori*-mediated effect on NSAID-induced change in prostaglandin production would be a potential mechanism for any interaction of *H. pylori* and NSAIDs (*Soll et al.,*

1992). It has therefore been suggested that an interaction of NSAIDs with this infection could lead to increased mucosal damage and perhaps explain the higher incidence of complications related to NSAIDs (*Graham and Smith, 1988*).

The eradication of H-pylori infection was found to reduce incidence of relapse and if H-pylori confirmed to be eradicated one month after treatment, the risk of recurrence is extremely low, maintenance treatment is not required and complicated peptic ulcer are less likely to rebleed (*Beeching and Harries, 1994*). It is therefore generally agreed upon that all patients with proven ulcer disease need antibiotic treatment, as long as infection with H. Pylori has been established.

It is difficult to state with assurance which regimen of eradication of H. Pylori is clinically optimal, although it is clear that eradication rates of 80 to 90% are achievable with some regimens, including triple therapy (*Perston, 1994*) and quadruple therapy (*De Boer et al., 1998*).

AIM OF THE WORK